Enhancer of zeste homolog 2 overexpression in nasopharyngeal carcinoma: An independent poor prognosticator that enhances cell growth

International Journal of Radiation Oncology Biology Physics

Volumn 82, Issue 2, 2012, Pages 597-604

  Hwang, Chung Feng ^a   Huang, Hsuan Ying ^a   Chen, Chang Han ^a   Chien, Chih Yen ^a   Hsu, Yao Chung ^a   Li, Chien Feng ^b,c   Fang, Fu Min ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

EZH2; Nasopharyngeal carcinoma; Proliferation; Survival

Indexed keywords

BIOPSY SAMPLES; CELL LINES; CONTINUOUS VARIABLES; DISEASE PROGRESSION; DISEASE-SPECIFIC SURVIVALS; ENDOGENOUS EXPRESSION; EXPRESSION LEVELS; EZH2; GROWTH ACTIVITY; HISTONE METHYLATION; IMMUNOBLOTTING; IMMUNOLABELING; KEY COMPONENT; MULTIVARIATE MODELS; NASOPHARYNGEAL CARCINOMA; OVER-EXPRESSION; OVERALL SURVIVAL; PROLIFERATION; REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SEMI-QUANTITATIVE; SURVIVAL; TARGET GENES;

ALKYLATION; CELL CULTURE; CELLS; GENES; GROWTH KINETICS; POLYMERASE CHAIN REACTION; RNA; TISSUE; TRANSCRIPTION;

CELL GROWTH;

MESSENGER RNA; TRANSCRIPTION FACTOR EZH2;

ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; DISEASE SPECIFIC SURVIVAL; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; NASOPHARYNX CARCINOMA; NONHUMAN; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ADULT; AGED; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; DNA-BINDING PROTEINS; FEMALE; GENE SILENCING; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NASOPHARYNX; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; RNA, MESSENGER; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 84862956349     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.11.062     Document Type: Article

References (31)

1. J.P.B. Chan, and T.T. Kuo Nasopharyngeal carcinoma World Health Organization classification of tumors - pathology & genetics: Head and neck tumors 2005 IARC Press Lyon, France 85 97
2. M.C. Yu, and J.M. Yuan Epidemiology of nasopharyngeal carcinoma Semin Cancer Biol 12 2002 421 429
3. K.W. Lo, K.F. To, and D.P. Huang Focus on nasopharyngeal carcinoma Cancer Cell 5 2004 423 428
4. F.M. Fang, C.Y. Chien, and C.F. Li Effect of S-phase kinase-associated protein 2 expression on distant metastasis and survival in nasopharyngeal carcinoma patients Int J Radiat Oncol Biol Phys 73 2009 202 207
5. F.M. Fang, W.L. Tsai, and S.F. Go Implications of quantitative tumor and nodal regression rates for nasopharyngeal carcinomas after 45 Gy of radiotherapy Int J Radiat Oncol Biol Phys 50 2001 961 969
6. F.L. Greene, D.L. Page, and D.I. Fleming Pharynx F.L. Greene, D.L. Page, D.I. Fleming, American Joint Committee on Cancer (AJCC) Cancer Staging Manual 6th ed 2002 Springer-Verlag New York 33 45
7. R. Cao, L. Wang, and H. Wang Role of histone H3 lysine 27 methylation in Polycomb-group silencing Science 298 2002 1039 1043
8. G. Laible, A. Wolf, and R. Dorn Mammalian homologues of the Polycomb-group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S. cerevisiae telomeres EMBO J 16 1997 3219 3232
9. S. Varambally, S.M. Dhanasekaran, and M. Zhou The polycomb group protein EZH2 is involved in progression of prostate cancer Nature 419 2002 624 629
10. A.P. Bracken, D. Pasini, and M. Capra EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer EMBO J 22 2003 5323 5335
11. C.G. Kleer, Q. Cao, and S. Varambally EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells Proc Natl Acad Sci U S A 100 2003 11606 11611
12. K. Kidani, M. Osaki, and T. Tamura High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas Oral Oncol 45 2009 39 46
13. Y. Matsukawa, S. Semba, and H. Kato Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer Cancer Sci 97 2006 484 491
14. M. Sasaki, H. Ikeda, and K. Itatsu The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma Lab Invest 88 2008 873 882
15. T. Sudo, T. Utsunomiya, and K. Mimori Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma Br J Cancer 92 2005 1754 1758
16. C.T. Lin, W.Y. Chan, and W. Chen Characterization of seven newly established nasopharyngeal carcinoma cell lines Lab Invest 68 1993 716 727
17. C.T. Lin, C.I. Wong, and W.Y. Chan Establishment and characterization of two nasopharyngeal carcinoma cell lines Lab Invest 62 1990 713 724
18. S.T. Tsai, S.Y. Fang, and Y.T. Jin Analysis of the expression of Fas-L in nasopharyngeal carcinoma tissues Oral Oncol 35 1999 421 424
19. S.W. Tsao, Y. Liu, and X. Wang The association of E-cadherin expression and the methylation status of the E-cadherin gene in nasopharyngeal carcinoma cells Eur J Cancer 39 2003 524 531
20. R.J. Bryant, N.A. Cross, and C.L. Eaton EZH2 promotes proliferation and invasiveness of prostate cancer cells Prostate 67 2007 547 556
21. P.A. Croonquist, and B. Van Ness The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype Oncogene 24 2005 6269 6280
22. Karanikolas BD, Figueiredo ML, Wu L. Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines. Prostate;70:675-688.
23. H.P. Visser, M.J. Gunster, and H.C. Kluin-Nelemans The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma Br J Haematol 112 2001 950 958
24. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
25. C.F. Hwang, C.L. Cho, and C.C. Huang Loss of cyclin D1 and p16 expression correlates with local recurrence in nasopharyngeal carcinoma following radiotherapy Ann Oncol 13 2002 1246 1251
26. D. Pasini, A.P. Bracken, and K. Helin Polycomb group proteins in cell cycle progression and cancer Cell Cycle 3 2004 396 400
27. Y. Yonemitsu, F. Imazeki, and T. Chiba Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma Hum Pathol 40 2009 1304 1311
28. A. Sparmann, and M. van Lohuizen Polycomb silencers control cell fate, development and cancer Nat Rev Cancer 6 2006 846 856
29. Y. Kotake, R. Cao, and P. Viatour pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4alpha tumor suppressor gene Genes Dev 21 2007 49 54
30. T. Tonini, L. Bagella, and G. D'Andrilli Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A Oncogene 23 2004 4930 4937
31. I.H. Su, M.W. Dobenecker, and E. Dickinson Polycomb group protein ezh2 controls actin polymerization and cell signaling Cell 121 2005 425 436